Skip to search boxSkip to navigationSkip to main content

S-nitrosylation is required for β2AR desensitization and experimental asthma

  • Fabio V. Fonseca
    ,
  • Thomas M. Raffay
    ,
  • Kunhong Xiao
    ,
  • Precious J. McLaughlin
    ,
  • Zhaoxia Qian
    ,
  • Zachary W. Grimmett
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

The β2-adrenergic receptor (β2AR), a prototypic G-protein-coupled receptor (GPCR), is a powerful driver of bronchorelaxation, but the effectiveness of β-agonist drugs in asthma is limited by desensitization and tachyphylaxis. We find that during activation, the β2AR is modified by S-nitrosylation, which is essential for both classic desensitization by PKA as well as desensitization of NO-based signaling that mediates bronchorelaxation. Strikingly, S-nitrosylation alone can drive β2AR internalization in the absence of traditional agonist. Mutant β2AR refractory to S-nitrosylation (Cys265Ser) exhibits reduced desensitization and internalization, thereby amplifying NO-based signaling, and mice with Cys265Ser mutation are resistant to bronchoconstriction, inflammation, and the development of asthma. S-nitrosylation is thus a central mechanism in β2AR signaling that may be operative widely among GPCRs and targeted for therapeutic gain.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3089-3102.e7

Journal (Volume, Issue Number)

Molecular Cell (Volume 82, Issue 16)

Publication milestones

  • Published - 08/18/2022

Publication status

Published - 08/18/2022

ISSN

1097-2765

Publication IDs

  • Scopus: 85135385874
  • PubMed: 35931084

Publication metrics

Metrics

Fractional count
1
Fractional count
0.06
Fractional count
16
Fractional count
0.94
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Social media
36
Mentions
3
Citation count
76
Captures
16

Funding Details

The authors thank Puneet Seth for technical assistance, and Robert Lefkowitz, Howard Rockman (Duke University), and Walter Koch (Temple University) for helpful discussions. Funded by NIH grants P01 HL075443, P01 HL128192, P01 HL158507, R01 HL126900, and R01 DK119506. Conceptualization, F.V.F. and J.S.S.; methodology, F.V.F. T.M.R. B.W. A.H. J.D.R. and N.A.L.; formal analysis, F.V.F. T.M.R. D.T.H. N.A.L. R.T.P. and J.S.S.; investigation, F.V.F. T.M.R. K.X. B.W. P.J.M. Z.Q. Z.W.G. A.H. N.A. D.T.H. B.A.C. N.A.L. and R.T.P.; writing—original draft, R.T.P. and F.V.F.; writing—review and editing, T.M.R. B.A.C. and J.D.R.; and supervision, project administration, and funding acquisition, J.S.S. J.S.S. has patents relating to nitrosylation, is a founder of SNO bio, and serves as a paid consultant to NNOXX, which is developing NO-based technology. CWRU and UHCMC have management plans in place. The authors thank Puneet Seth for technical assistance, and Robert Lefkowitz, Howard Rockman (Duke University), and Walter Koch (Temple University) for helpful discussions. Funded by NIH grants P01 HL075443 , P01 HL128192 , P01 HL158507 , R01 HL126900 , and R01 DK119506 .
FundersFunding numbers
UHCMC
-
CWRU
-
NIH
-
NIGMS
R35GM145284, T32GM007250, R01GM130142
-
16KK0181
NHLBI
P01HL128192, P01HL075443, P01HL158507, R01HL126900
NIDDK
R01DK119506